Related Experiment Video
Updated: May 16, 2026
X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
Published on: December 9, 2022
Anti-breast cancer potential of daidzein in rodents
Aims:
This study was carried out to explore anti-breast cancer potential of isoflavone daidzein or its related compounds using appropriate animal models and their anti-tumor mechanism.
Main Methods:
Daidzein or its major metabolite equol at a dose molar equivalent to tamoxifen [1.0 mg(2.7 μmol)/kg or 10 mg (27 μmol)/kg/day] was treated orally to rats bearing 7,12-dimethylbenz(a)anthracene(DMBA)-induced mammary tumors or ovariectomized athymic nude mice implanted with human MCF-7 breast cancer xenograft and an estrogen pellet. The growth of tumors was monitored for several weeks after the treatment. The cell-cycle and apoptotic stages in mammary tumors collected from rats were analyzed by flow cytometry. Immunohistochemistry analysis was also used to determine the expression of caspase-3.
Key Findings:
Oral treatment with daidzein or equol at a human equivalent dose suppressed the growth of both DMBA-induced mammary tumors and human MCF-7 breast cancer xenografts in rodents, the inhibitory activity being superior to that of genistein or tamoxifen. Strong apoptosis induced by daidzein or equol contributes to the anti-tumor potential.
Significance:
Daidzein and its metabolite equol showed the potential of inhibiting the growth of mammary tumors in rodents. Daidzein or equol could be used as a core structure to design new drugs for breast cancer therapy. Our results indicate that consumption of daidzein may protect against breast cancer.
Insights
Daidzein and its metabolite equol show significant anti-breast cancer potential by suppressing tumor growth and inducing apoptosis in animal models. These compounds may serve as a basis for new breast cancer therapies.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Breast cancer remains a leading cause of mortality in women worldwide.
- Isoflavones, such as daidzein, are plant-derived compounds with potential chemopreventive properties.
- Understanding the anti-tumor mechanisms of daidzein and its metabolites is crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To investigate the anti-breast cancer effects of daidzein and its metabolite equol.
- To explore the anti-tumor mechanisms of these compounds using animal models.
- To evaluate their potential as a basis for new breast cancer drugs.
Main Methods:
- Oral administration of daidzein or equol to rats with 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary tumors.
- Treatment of ovariectomized athymic nude mice bearing human MCF-7 breast cancer xenografts.
- Monitoring tumor growth, analyzing cell-cycle and apoptotic stages via flow cytometry, and assessing caspase-3 expression through immunohistochemistry.
Main Results:
- Daidzein and equol significantly suppressed the growth of both DMBA-induced mammary tumors and human MCF-7 breast cancer xenografts in rodents.
- The inhibitory activity of daidzein and equol was found to be superior to that of genistein or tamoxifen.
- Strong induction of apoptosis by daidzein and equol was identified as a key contributor to their anti-tumor potential.
Conclusions:
- Daidzein and its metabolite equol demonstrate significant potential in inhibiting mammary tumor growth in rodent models.
- These compounds can serve as a structural basis for the development of novel breast cancer therapeutics.
- Dietary intake of daidzein may offer protection against breast cancer development.
